Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
Sanaa M Kamal1,21Department of Medicine, Division of Hepatology, Gastroenterology and Tropical Medicine, Ain Shams Faculty of Medicine, Cairo, Egypt, 2Department of Medicine, Salman Bin Abdul Aziz College of Medicine, Kingdom of Saudi ArabiaAbstract: Hepatitis C virus (HCV) has emerged as a major v...
Guardado en:
Autor principal: | Kamal SM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0f57efea98f34f8cbddc989454b0f0d6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
por: Lim TR
Publicado: (2014) -
Interferon-free combination therapies for the treatment of hepatitis C: current insights
por: Holmes JA, et al.
Publicado: (2015) -
Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
por: JIANG Jun
Publicado: (2021) -
How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B
por: DING Yang
Publicado: (2021) -
Patients with chronic hepatitis B virus infection in the indeterminate phase may benefit from antiviral therapy
por: XU Jinghang
Publicado: (2021)